Innate Pharma (IPHA) Consolidated Net Income (2020 - 2024)
Historic Consolidated Net Income for Innate Pharma (IPHA) over the last 5 years, with Q4 2024 value amounting to -$52.9 million.
- Innate Pharma's Consolidated Net Income fell 54905.28% to -$52.9 million in Q4 2024 from the same period last year, while for Jun 2025 it was -$61.0 million, marking a year-over-year decrease of 64365.26%. This contributed to the annual value of -$133652.4 for FY2022, which is 9845.94% up from last year.
- Latest data reveals that Innate Pharma reported Consolidated Net Income of -$52.9 million as of Q4 2024, which was down 54905.28% from -$8.1 million recorded in Q4 2023.
- In the past 5 years, Innate Pharma's Consolidated Net Income registered a high of -$59145.8 during Q4 2022, and its lowest value of -$75.3 million during Q4 2020.
- In the last 5 years, Innate Pharma's Consolidated Net Income had a median value of -$52.0 million in 2021 and averaged -$37.7 million.
- As far as peak fluctuations go, Innate Pharma's Consolidated Net Income surged by 9988.63% in 2022, and later crashed by 1367083.18% in 2023.
- Quarter analysis of 5 years shows Innate Pharma's Consolidated Net Income stood at -$75.3 million in 2020, then soared by 30.91% to -$52.0 million in 2021, then skyrocketed by 99.89% to -$59145.8 in 2022, then crashed by 13670.83% to -$8.1 million in 2023, then tumbled by 549.05% to -$52.9 million in 2024.
- Its Consolidated Net Income was -$52.9 million in Q4 2024, compared to -$8.1 million in Q4 2023 and -$59145.8 in Q4 2022.